Tremor & Other Movement Symptoms

📋 Key Information Summary

📋

Essential tremor (ET) is the most common movement disorder worldwide, affecting approximately 4% of adults over 40 years in Australia; prevalence increases with age.
ET is a clinical diagnosis — bilateral, symmetric postural and/or kinetic tremor of the hands and forearms lasting ≥3 years, with or without head/voice tremor, in the absence of other neurological signs.
Key differentiating features from Parkinson's disease (PD) tremor: ET is predominantly postural/kinetic (not resting), symmetric (not unilateral), improves with small amounts of alcohol, and is not associated with bradykinesia or rigidity.
Neuroimaging (MRI brain) is not routinely required for classic ET — consider imaging when atypical features are present (asymmetry, focal neurological signs, acute onset, age of onset <40 years).
First-line pharmacotherapy for ET is propranolol (40–320 mg/day PO) or primidone (62.5–750 mg/day PO); choice depends on comorbidities, patient preference, and contraindications.
Propranolol is contraindicated in severe asthma/COPD, heart block, and decompensated heart failure; start low (20 mg BD) and titrate slowly.
Primidone should be initiated at a very low dose (62.5 mg nocte) and titrated slowly to minimise acute sedation, dizziness, and ataxia — up to 30% of patients cannot tolerate it.
Second-line agents include topiramate, gabapentin, clonazepam, and botulinum toxin A (for head/voice tremor or refractory hand tremor); deep brain stimulation (DBS) of the ventral intermediate nucleus (Vim) is reserved for medically refractory, functionally disabling tremor.
Functional movement disorders (FMD) are characterised by inconsistency, distractibility, entrainment, and positive clinical signs (e.g., Hoover's sign, co-contraction sign) — they are not diagnoses of exclusion.
Diagnose FMD with confidence using positive clinical features; communicate the diagnosis clearly, explain the mechanism, and avoid language that implies the symptoms are feigned or "all in your head."
Functional tremor — look for distractibility (tapping contralateral hand or performing mental arithmetic changes tremor amplitude), entrainment (tremor frequency shifts to match a cued rhythm), and variable amplitude that does not fit a classic neurological pattern.
Referral to specialised physiotherapy (movement disorder-focused) and psychology (CBT, acceptance and commitment therapy) is the mainstay of FMD management — pharmacotherapy has limited evidence.
Functional impact assessment is critical in both ET and FMD — use standardised tools (ET rating scales, PDQ-39 equivalent, WHODAS 2.0) to guide treatment decisions and determine eligibility for advanced therapies.
Aboriginal and Torres Strait Islander Australians may face barriers to specialist assessment; consider telehealth-supported movement disorder clinics and culturally safe communication when discussing functional neurological symptoms.

Introduction & Australian Epidemiology

Tremor is defined as an involuntary, rhythmic, oscillatory movement of a body part and is the most common movement symptom encountered in primary care. Movement symptoms encompass a broader spectrum including tremor, myoclonus, dystonia, chorea, tics, and functional (psychogenic) movement disorders. This guideline focuses on essential tremor, its differentiation from Parkinsonian tremor, evidence-based treatment, and functional movement disorders — a frequently misdiagnosed but important cause of disabling movement symptoms.

In Australia, essential tremor affects an estimated 4–5% of adults aged over 40 years, with prevalence rising to 10–15% in those over 65 years. It is approximately four to ten times more prevalent than Parkinson's disease. The condition is associated with significant functional impairment, reduced quality of life, increased fall risk, and higher rates of social isolation, particularly in elderly populations.

Functional movement disorders account for approximately 2–5% of referrals to Australian movement disorder clinics and up to 15–20% of patients seen in subspecialist practice. They affect younger adults (mean age of onset 30–40 years) more frequently and are associated with significant disability and healthcare utilisation. Misdiagnosis rates remain high, and the average time from symptom onset to correct diagnosis exceeds 2–5 years in many series.

This article provides an Australian clinical framework for the assessment and management of essential tremor and functional movement disorders, aligned with current Therapeutic Guidelines (eTG), Australian and international movement disorder society recommendations, and PBS-listed treatment options.

Essential Tremor — Clinical Diagnosis

Definition & Diagnostic Criteria

Essential tremor (ET) is a chronic, bilateral, primarily symmetric postural and/or kinetic tremor involving the hands and forearms. The International Parkinson and Movement Disorder Society (MDS) consensus criteria (2018) classify ET into:

ET — "Classic": Bilateral upper limb tremor (postural or kinetic) lasting ≥3 years, with or without tremor in other locations (head, voice, lower limbs), and no other neurological signs.
ET-plus: ET with additional neurological signs of uncertain significance (e.g., mildly impaired tandem gait, questionable dystonic posturing, subtle memory complaints) — this category acknowledges the phenotypic heterogeneity of ET.

Clinical Assessment

A focused history and neurological examination are essential. Key elements include:

Assessment Domain	Key Questions / Examination
Tremor onset & evolution	Gradual onset (years to decades); usually insidious; ask about family history (50% have affected first-degree relative, autosomal dominant with variable penetrance)
Tremor context	Postural (hands outstretched), kinetic (finger-to-nose, pouring water, drinking from a cup), writing, eating, speaking
Alcohol response	Classically improves with small amounts of ethanol — useful diagnostically but NOT a treatment strategy
Functional impact	Writing, eating, drinking, dressing, occupational tasks, driving, social embarrassment
Medications & substances	Exacerbating agents: sodium valproate, lithium, β-agonists, caffeine, corticosteroids, amiodarone
Neurological examination	Postural tremor (arms outstretched), kinetic tremor (finger-to-nose), rest tremor (hands relaxed in lap), tone, bradykinesia, gait, tandem walk, dystonic posturing

Differentiation from Parkinson's Disease Tremor

Feature	Essential Tremor	Parkinson's Disease Tremor
Tremor type	Postural and kinetic (predominantly); may have mild rest component in advanced disease	Resting (predominantly); may have postural component (re-emergent tremor)
Symmetry	Bilateral and symmetric	Asymmetric onset (ipsilateral to initial bradykinesia)
Frequency	4–12 Hz (typically 6–8 Hz)	4–6 Hz
Pill-rolling	No	Classic (thumb-index)
Alcohol response	Often improves	No improvement
Associated features	Head/voice tremor (may occur in isolation); no rigidity or bradykinesia	Bradykinesia, rigidity, postural instability, micrographia, masked facies
Family history	Positive in ~50%	Positive in ~15%
Head tremor	Common (yes-yes or no-no)	Uncommon

⚠️

Red flags requiring urgent investigation: Acute/subacute onset (days to weeks), unilateral tremor with progressive features, associated focal neurological deficits, rapidly progressive course, new onset in a patient on neuroleptic medication (drug-induced parkinsonism), or suspected Wilson's disease (age <40 years with movement disorder — check serum caeruloplasmin and 24-hour urinary copper).

When to Image

Neuroimaging is not routinely required for classic ET with typical features. Consider MRI brain when:

Atypical features — asymmetric tremor, focal neurological signs, acute onset
Age of onset <40 years (consider Wilson's disease, other structural causes)
Diagnostic uncertainty between ET and PD — DaT-SPECT (dopamine transporter scan) may be considered to confirm nigrostriatal denervation in suspected PD; normal DaT-SPECT supports ET (available at major Australian nuclear medicine centres, MBS item 61409)
Suspected structural cause (e.g., midbrain lesion, cerebellar pathology)

ℹ️

DaT-SPECT availability in Australia: Available at major metropolitan hospitals and nuclear medicine centres. Requires referral from a neurologist or geriatrician. MBS item 61409 ( dopamine transporter imaging) is listed for differentiation of essential tremor from parkinsonian syndromes. Wait times may be 2–6 weeks in public settings.

Investigations

Essential

Thyroid function tests (TFTs)

Exclude hyperthyroidism as a cause of enhanced physiological tremor — MBS item 66709

Essential

Serum caeruloplasmin & 24-hour urinary copper

Mandatory if age <40 years with tremor or any movement disorder — exclude Wilson's disease. MBS item 66577

Available

Serum copper, liver function tests, FBC

Supportive for Wilson's disease workup; also exclude metabolic causes. MBS items 66554, 66551

Available

Medication review

Review for tremorogenic medications (valproate, lithium, β-agonists, caffeine, amiodarone, corticosteroids)

Referral

DaT-SPECT (Dopamine Transporter Scan)

For diagnostic uncertainty between ET and PD. Available at major metropolitan nuclear medicine centres. MBS item 61409. Requires specialist referral.

Referral

MRI Brain

When atypical features present, acute onset, or structural cause suspected. MBS item 63090 (MRI brain without contrast). Specialist referral recommended.

Treatment of Essential Tremor

Principles of Management

Treatment should be guided by functional impact, not tremor amplitude alone. Many patients with mild ET require no pharmacotherapy. Treatment initiation is indicated when tremor interferes with activities of daily living (writing, eating, drinking, occupational tasks) or causes significant social distress. A shared decision-making approach, incorporating patient goals and preferences, is essential.

Functional Impact Assessment

Assess the functional impact of tremor before and during treatment using validated tools:

Essential Tremor Rating Assessment Scale (TETRAS): Clinician-rated and patient-rated scales capturing performance and ADL impact — recommended by the MDS
Quality of Life in Essential Tremor (QUEST): Patient-reported outcome measure for tremor-specific quality of life
Functional Assessment: Ask specifically about writing, drinking from a cup, eating with utensils, using tools, using a smartphone, dressing, grooming, driving, and social/occupational participation

First-Line Pharmacotherapy

💊

Propranolol

Inderal® · Deralin® · Generic · Non-selective β-blocker

Adult dose Start 20–40 mg PO BD; titrate by 20–40 mg every 1–2 weeks; target 80–320 mg/day (usually 120–240 mg/day in divided doses or long-acting once daily)

Paediatric dose 0.5–1 mg/kg/day PO in 2–3 divided doses (paediatric use off-label; specialist guidance recommended)

Renal adjustment No specific adjustment; use with caution in severe renal impairment

Hepatic adjustment Reduce dose in significant hepatic impairment; monitor closely

Key side effects Fatigue, dizziness, bradycardia, cold extremities, bronchospasm, hypotension, sexual dysfunction, masking of hypoglycaemia in diabetes

Contraindications Asthma (severe), COPD (significant), heart block (2nd/3rd degree), decompensated heart failure, severe peripheral vascular disease, phaeochromocytoma (without α-blockade)

PBS status ✔ PBS General Benefit

💊

Primidone

Mysoline® · Barbiturate-class anticonvulsant

Adult dose Start 62.5 mg PO at night; increase by 62.5 mg weekly; target 250–750 mg/day in 2–3 divided doses (typical effective dose 250–500 mg/day)

Paediatric dose Not routinely used in paediatric ET; specialist guidance required

Renal adjustment Use with caution; active metabolites (phenylethylmalonamide, PEMA) accumulate; dose reduction may be needed in eGFR <30 mL/min

Hepatic adjustment Avoid in significant hepatic impairment

Key side effects Acute: sedation, dizziness, nausea, ataxia (first-dose phenomenon — up to 30% discontinue); chronic: cognitive effects, depression, blood dyscrasias (rare), megaloblastic anaemia

Important notes Must counsel patients about first-dose phenomenon — the first dose (even 62.5 mg) may cause profound sedation and disequilibrium. Advise to take at bedtime. 20–30% of patients cannot tolerate primidone.

PBS status ✔ PBS General Benefit

✅

Choosing between propranolol and primidone: Propranolol is generally preferred as first-line due to better tolerability. Primidone is a good alternative when β-blockers are contraindicated (asthma, heart block) or ineffective. Both are considered first-line by MDS and eTG. Some patients benefit from combination therapy at lower doses of each agent.

Second-Line Agents

💊

Topiramate

Topamax® · Generic · Anticonvulsant

Adult dose Start 25 mg PO nocte; titrate by 25 mg weekly; target 100–400 mg/day in divided doses

Key side effects Weight loss, paraesthesiae, cognitive impairment ("dopamax"), kidney stones, metabolic acidosis, teratogenicity (Category D)

PBS status ⚠️ Authority Required (for epilepsy/migraine — off-label for ET)

💊

Gabapentin

Neurontin® · Generic · GABA analogue

Adult dose Start 300 mg PO TDS; titrate to 1200–3600 mg/day in divided doses

Renal adjustment Dose reduction required — 200–700 mg/day if eGFR 30–59; 100–300 mg/day if eGFR 15–29; 100 mg/day if eGFR <15

Key side effects Sedation, dizziness, weight gain, peripheral oedema

PBS status ⚠️ Authority Required (for neuropathic pain — off-label for ET)

💊

Clonazepam

Rivotril® · Generic · Benzodiazepine

Adult dose Start 0.25–0.5 mg PO nocte; titrate to 0.5–2 mg/day in divided doses

Key side effects Sedation, dependence, cognitive impairment, falls risk in elderly

Important notes Generally reserved for refractory cases due to dependence risk. Avoid long-term use where possible.

PBS status ✔ PBS General Benefit

💊

Botulinum Toxin A (IncobotulinumtoxinA)

Xeomin® · Botox® · Neurotoxin

Indication Refractory hand tremor, head tremor, voice tremor (when oral agents have failed)

Hand tremor dose 50–200 units per session divided among wrist flexors/extensors and forearm muscles (guided by EMG); higher doses increase weakness risk

Head/voice tremor Head tremor: sternocleidomastoid, splenius capitis, trapezius; Voice tremor: thyroarytenoid injection (laryngologist/ENT required)

Frequency Every 12–16 weeks

Key side effects Hand weakness (dose-dependent), dysphagia (head/neck injection), injection site pain

PBS status ⚠️ Authority Required (cervical dystonia; ET use is off-label in Australia)

Advanced / Surgical Therapy

ℹ️

Deep Brain Stimulation (DBS): Vim-DBS (ventral intermediate nucleus of the thalamus) is effective for severe, medically refractory ET with tremor reduction of 60–90% in most series. Indicated when tremor causes significant functional disability despite adequate trials of at least two first-line agents. Available at major Australian centres (Royal Melbourne, Royal Brisbane, Westmead, Flinders). Requires assessment by a movement disorder neurosurgeon. Focused ultrasound thalamotomy (MRgFUS) is an emerging incisionless alternative available at select centres.

Non-Pharmacological Strategies

Weighted utensils and writing devices (weighted pens, adaptive cups)
Occupational therapy for adaptive strategies and workplace modifications
Avoidance of tremorogenic substances (caffeine, sympathomimetics)
Stress management and anxiety treatment (anxiety worsens ET)
Physiotherapy for balance and fall prevention in elderly patients with gait involvement
Psychological support for social withdrawal and embarrassment

Functional Movement Disorders

Overview

Functional movement disorders (FMD), also termed psychogenic movement disorders, are characterised by involuntary movements that are clinically inconsistent, incompatible with recognised neurological disease, and associated with positive clinical signs. FMD is not a diagnosis of exclusion — it should be diagnosed on the basis of positive clinical features that demonstrate the functional nature of the symptoms. The DSM-5 classifies these as "Functional Neurological Symptom Disorder (Conversion Disorder)" with the specifier "with abnormal movement."

🚨

Critical principle: FMD is a real neurological condition — not malingering, not "made up," and not the patient's fault. Patients with FMD are typically in genuine distress with significant disability. The diagnosis should be communicated with empathy, clarity, and confidence. Avoid dismissive language ("there's nothing wrong") or attribution to purely psychological causes without evidence.

Clinical Clues to Diagnosis — Positive Signs

The following positive clinical signs help identify FMD with specificity. A single positive sign is supportive; multiple signs strengthen the diagnosis significantly.

Positive Sign	Description	How to Elicit
Distractibility	Tremor amplitude decreases, changes character, or disappears during complex contralateral motor or cognitive tasks	Ask patient to tap fingers of the opposite hand in a complex rhythm, perform serial 7s, or name animals while observing tremor
Entrainment	Functional tremor changes frequency to match an externally cued rhythm	Ask patient to tap with the unaffected hand at a given frequency (e.g., 3 Hz, then 5 Hz); functional tremor will shift to match
Hoover's sign	Involuntary hip extension on the "weak" side is activated by contralateral hip flexion against resistance	Supine: test hip extension on the affected side (weak/absent); then ask patient to flex the contralateral hip against resistance — extension on the affected side re-emerges
Co-contraction sign	Simultaneous contraction of agonist and antagonist muscles producing rigidity that is not velocity-dependent	Passive movement of the affected limb — feel for co-contraction of both muscle groups simultaneously (unlike true rigidity which has a velocity-dependent quality)
Tremor variability	Tremor amplitude, frequency, or distribution changes significantly between observation periods or with attention directed to the affected limb	Observe tremor with the patient aware and unaware of being watched; compare tremor during conversation versus focused attention
Arm drop	When the affected arm is lifted and released, it falls slowly and avoids the face/body (inconsistent with true weakness)	Lift the patient's arm above the face and release — a genuinely weak arm falls onto the face; a functional arm diverts
Thigh abductor sign	In a patient with apparent leg weakness, hip abduction against resistance is possible when tested with the patient supine and the contralateral leg performing a different task	Test hip abduction strength in isolation (weak) versus during contralateral hip adduction against resistance

Functional Tremor — Specific Features

Sudden onset (often can recall the exact moment) with maximal severity at onset ("hitting a wall") — contrast with the gradual onset of ET
Resting tremor that is also prominent on posture and kinetic tasks — does not follow a classical neurological pattern
Spontaneous remissions and relapses with inconsistent distribution
Associated with other functional neurological symptoms (weakness, sensory disturbance, non-epileptic seizures, gait disorder)
Tremor may cease during contralateral rhythmic tapping (entrainment) or when attention is diverted
Classic features of ET (symmetric postural/kinetic, family history, alcohol-responsive) are typically absent

Communication Strategies

The diagnostic conversation is the most important therapeutic intervention. Research consistently shows that a well-communicated diagnosis reduces symptoms, healthcare utilisation, and diagnostic uncertainty.

1

Validate and acknowledge

"Your symptoms are real. I can see the tremor. You are not imagining this, and you are not making it up."

2

Explain the diagnosis positively

"I found specific signs during the examination that tell me your brain is not sending the right signals to your muscles. This is a recognised neurological condition called a functional movement disorder."

3

Use an analogy

"Think of it like a software problem in the brain rather than a hardware problem. The brain's 'software' for controlling movement has become disrupted — the wiring is intact, but the signals are being sent incorrectly."

4

Explain the mechanism

"This can happen after stress, injury, illness, or sometimes for no obvious reason. It does NOT mean it is 'in your head' or imaginary — the brain is physically producing these symptoms through abnormal signal patterns."

5

Offer hope and a treatment plan

"The good news is that functional movement disorders are potentially reversible with the right treatment. I would like to refer you to a physiotherapist who specialises in movement disorders and a psychologist."

⚠️

Language to avoid: "It's all in your head," "There's nothing wrong," "It's psychosomatic," "You're just stressed," "Your tests are normal so it can't be neurological." These phrases undermine the therapeutic relationship, reduce treatment engagement, and are factually incorrect — functional neurological symptoms are neurological, not "just psychological."

Investigations in FMD

The primary role of investigations is to exclude co-existing organic pathology, not to "diagnose" FMD (which is a clinical diagnosis). Avoid unnecessary or repeated investigations, which can reinforce health anxiety.

Routine blood tests if not recently performed (TFTs, FBC, EUC, LFTs, glucose, calcium, magnesium)
Brain MRI if any atypical features or diagnostic uncertainty
EEG if non-epileptic seizures are part of the presentation
Video recording of the movement disorder (with patient consent) — invaluable for demonstration of positive signs and for specialist review
Avoid using investigations as the sole basis for diagnosis — a normal MRI does not confirm FMD any more than a normal MRI in ET

Management — Referral & Multidisciplinary Approach

The mainstay of FMD management is multidisciplinary rehabilitation. Evidence supports physiotherapy and psychological therapy as the two pillars of treatment.

Physiotherapy

Referral to a physiotherapist with experience in neurological/functional movement disorders (not general physiotherapy)
Focus on retraining automatic motor control — using attention-diverting strategies, graded motor relearning, and movement reprogramming
Goals-based approach with measurable functional outcomes
Sessions typically 1–2 times per week for 8–12 weeks with reassessment
Available through public hospital outpatient departments (variable wait times 4–12 weeks) or privately (Medicare chronic disease management plan — 5 allied health sessions per year, MBS item 10950)

Psychology

Referral to a psychologist experienced in functional neurological disorders
Cognitive Behavioural Therapy (CBT) — evidence for functional neurological symptoms; addresses illness beliefs, avoidance behaviour, and symptom-focused attention
Acceptance and Commitment Therapy (ACT) — emerging evidence; helps patients develop psychological flexibility around symptoms
Trauma-informed assessment — some patients have comorbid PTSD, anxiety, or depression that may benefit from treatment
Mental Health Treatment Plan (MHTP) — Medicare rebate for up to 10 psychology sessions per year (MBS item 80110)
Avoid reflexive psychotropic prescribing — antidepressants are not first-line for FMD unless comorbid mood/anxiety disorder is present

Specialist Neurology Referral

Referral to a movement disorder neurologist is recommended for diagnostic confirmation and ongoing management
Many movement disorder specialists run dedicated FMD clinics in Australian capital cities
Telehealth referral may be appropriate for regional and remote patients (MBS telehealth items available)

Pharmacotherapy in FMD

There is no established pharmacological treatment for FMD. Medications should target specific comorbidities:

Comorbid depression: SSRI (e.g., sertraline 50–200 mg/day PO) — PBS General Benefit
Comorbid anxiety: SSRI or SNRI; avoid benzodiazepines long-term
Sleep disturbance: Sleep hygiene, address anxiety; short-term melatonin if needed
Pain: Multimodal analgesia; avoid opioids

ℹ️

Prognosis of FMD: Approximately 50–70% of patients with FMD who receive early, confident diagnosis and appropriate multidisciplinary treatment show improvement or remission within 1–2 years. Poor prognostic factors include long duration of symptoms before diagnosis (>1 year), comorbid chronic pain, ongoing litigation/compensation claims, and poor engagement with rehabilitation. Early diagnosis and clear communication are the strongest predictors of good outcome.

Special Populations

🤰

Pregnancy

Propranolol: Generally considered safe in pregnancy; continue if well-controlled. Neonatal bradycardia and hypoglycaemia possible — monitor neonate post-delivery.

Primidone: Category D — avoid in pregnancy. Teratogenic risk (cleft palate, cardiac defects). Switch to propranolol before conception where possible.

Topiramate: Category D — contraindicated. Teratogenic (oral clefts).

Clonazepam: Category C — avoid if possible; risk of neonatal sedation and withdrawal. Use only if benefits clearly outweigh risks.

FMD in pregnancy: Functional symptoms may fluctuate with hormonal and psychological changes. Ensure psychological support continues. Multidisciplinary approach with obstetric team involvement.

Contraception and pre-conception counselling should be discussed for all women of childbearing age on anti-tremor medications, particularly primidone and topiramate.

👶

Paediatrics

ET in children: Rare but may present from age 6–8 years; strong family history typical. Consider Wilson's disease and other hereditary causes in all paediatric tremor cases.

Diagnosis: Must exclude Wilson's disease (caeruloplasmin, 24-hour urinary copper, slit-lamp examination for Kayser-Fleischer rings), medication effects, thyroid disease, and structural causes.

Treatment: Propranolol (0.5–1 mg/kg/day PO) is first-line; primidone not routinely used. Specialist paediatric neurology guidance recommended.

Functional symptoms in children: Increasingly recognised; school avoidance and bullying should be assessed. Paediatric psychology referral preferred. Family-based approaches are important.

Referral to paediatric neurology is recommended for all children presenting with new-onset tremor.

🧓

Elderly

Pharmacotherapy caution: Lower starting doses; slower titration. β-blockers increase falls risk and may worsen orthostatic hypotension in the elderly.

Primidone: Enhanced sensitivity to first-dose phenomenon; start at 31.25–62.5 mg. Sedation and ataxia risk increases significantly in older adults.

Cognitive effects: Topiramate and clonazepam may worsen cognition; avoid in dementia or significant cognitive impairment.

Functional assessment: Tremor-related falls risk should be assessed. Occupational therapy referral for home safety assessment and adaptive devices.

FMD in elderly: Often misdiagnosed as progressive neurological disease. Comorbid depression is common and should be treated. Psychogenic parkinsonism may mimic PD.

Consider enhanced physiological tremor from medications (valproate, lithium, bronchodilators) — medication review is essential before diagnosing ET in elderly patients.

🫘

Renal Impairment

Propranolol: No significant dose adjustment required; metabolised hepatically.

Primidone: Active metabolites (PEMA) accumulate in renal impairment; use cautiously and reduce dose if eGFR <30 mL/min.

Gabapentin: Dose reduction mandatory — see renal dosing table above. Dose proportional to eGFR.

Topiramate: Reduce dose in eGFR <70 mL/min; avoid if eGFR <30 mL/min (metabolic acidosis risk, stone risk).

🫁

Hepatic Impairment

Propranolol: Reduced first-pass metabolism; increase dose interval; monitor for hypotension and bradycardia.

Primidone: Metabolised hepatically; avoid in significant hepatic impairment (Child-Pugh B/C).

Topiramate: Primarily renal excretion; minimal hepatic adjustment needed.

Clonazepam: Hepatically metabolised; reduce dose and monitor sedation in hepatic impairment.

🛡️

Immunocompromised

Relevance: Immunosuppression per se does not alter tremor management, but consider opportunistic infections or medication-induced tremor (e.g., calcineurin inhibitors — tacrolimus, cyclosporin cause tremor in 20–30% of transplant patients).

Drug interactions: Propranolol is metabolised via CYP2D6 — check interactions with antifungals, antiretrovirals. Tacrolimus-induced tremor may respond to dose reduction or switching to everolimus.

FMD: Immunocompromised patients with FMD should receive standard multidisciplinary treatment; no specific modifications required.

Aboriginal and Torres Strait Islander Health Considerations

Aboriginal and Torres Strait Islander Health

Access to specialist care

Aboriginal and Torres Strait Islander Australians in remote and very remote areas have limited access to neurologists and movement disorder specialists. Telehealth-supported movement disorder consultations (available via MBS telehealth items) should be offered proactively. State-based outreach neurology services and visiting specialist programs (e.g., Northern Territory Specialist Outreach) can bridge this gap.

Diagnostic delays

Movement disorders may be under-recognised in Aboriginal and Torres Strait Islander communities due to reduced specialist access, competing health priorities (cardiovascular disease, diabetes, renal disease), and culturally different health-seeking patterns. Primary care clinicians in Aboriginal Community Controlled Health Organisations (ACCHOs) should consider ET and FMD in differential diagnoses of involuntary movements.

Wilson's disease screening

Wilson's disease may be underdiagnosed in Aboriginal and Torres Strait Islander populations. Any Aboriginal or Torres Strait Islander person presenting with tremor, movement disorder, or unexplained hepatic dysfunction under age 40 years should have Wilson's disease excluded (serum caeruloplasmin, 24-hour urinary copper, ophthalmological review for Kayser-Fleischer rings).

Cultural safety in FMD diagnosis

Functional neurological symptoms must be discussed with cultural sensitivity. Concepts of illness causation may differ, and a biomedical framework may not align with some patients' understanding. Engage Aboriginal Health Workers and Practitioners (AHWPs) in the diagnostic conversation. Avoid language implying psychological causation without culturally appropriate explanation. Yarning-based approaches to communication may enhance understanding and engagement.

Medication access in remote areas

Propranolol, primidone, and clonazepam are PBS-listed and available through Remote Area Aboriginal Health Services (Section 100 / Close the Gap PBS Co-payment Program). Ensure prescriptions are accessible through Remote Communities Pharmacies and Outreach programs. Where specialist input is required for botulinum toxin or DBS referral, travel assistance through Patient Assisted Travel Schemes (PATS — WA), Patient Travel Subsidy Scheme (PTSS — NT), or equivalent state programs should be facilitated.

Social and emotional wellbeing

Tremor and functional movement disorders significantly impact social and emotional wellbeing. Aboriginal and Torres Strait Islander patients should be offered culturally safe psychological support through ACCHOs and social and emotional wellbeing programs. The Australian Indigenous Doctors' Association (AIDA) framework for social and emotional wellbeing provides a holistic model that extends beyond Western psychiatric constructs. Consider referral to local Aboriginal counselling services where available.

📚 References

1. Bhatia KP, Bain P, Bajaj N, et al. Consensus Statement on the classification of tremors. From the task force on tremor of the International Parkinson and Movement Disorder Society. Mov Disord. 2018;33(1):75-87.
2. Louis ED, Ferreira JJ. How common is the most common adult movement disorder? Update on the worldwide prevalence of essential tremor. Mov Disord. 2010;25(5):534-541.
3. Deuschl G, Raethjen J, Hellriegel H, Elble R. Treatment of essential tremor. Lancet Neurol. 2011;10(6):582-590.
4. Espay AJ, Lang AE, Erro R, et al. Essential pitfalls in "essential" tremor. Mov Disord. 2017;32(3):325-331.
5. Edwards MJ, Stone J, Lang AE. From psychogenic movement disorder to functional movement disorder: it's time to change the name. Mov Disord. 2014;29(7):849-852.
6. Espay AJ, Aybek S, Carson A, et al. Current concepts in diagnosis and treatment of functional neurological disorders. JAMA Neurol. 2018;75(9):1132-1141.
7. Stone J, Carson A, Duncan R, et al. Which neurologic diseases are most likely to be misdiagnosed? The "functional" neurological disorders. Neurology. 2016;86(4):396-397.
8. National Health and Medical Research Council (NHMRC). Australian Guidelines for the Prevention and Control of Infection in Healthcare. Canberra: NHMRC; 2019. [Referenced for national clinical governance frameworks].
9. Australian Institute of Health and Welfare (AIHW). Aboriginal and Torres Strait Islander Health Performance Framework. Canberra: AIHW; 2023. [Accessed for ATSI health data and service delivery context].
10. Zesiewicz TA, Elble R, Louis ED, et al. Evidence-based guideline update: Treatment of essential tremor. Neurology. 2011;77(19):1752-1755.
11. Carson A, Stone J, Hibberd C, et al. Disability, distress and unemployment in neurology outpatients with symptoms "unexplained by organic disease." J Neurol Neurosurg Psychiatry. 2011;82(7):810-813.
12. Nielsen G, Stone J, Matthews A, et al. Physiotherapy for functional motor disorders: a consensus recommendation. J Neurol Neurosurg Psychiatry. 2015;86(10):1113-1119.
13. Royal Australian College of General Practitioners (RACGP). Management of neurological conditions in general practice. East Melbourne: RACGP; 2020.
14. National Stroke Foundation. Clinical Guidelines for Stroke Management. Melbourne: Stroke Foundation; 2022. [Referenced for functional neurological symptom differential context].
15. Paviour DC, Jäger HR, Wilkinson L, Jahanshahi M, Lees AJ. Is the cervical dystonia tremor clinically distinguishable from essential tremor? Eur J Neurol. 2006;13(7):735-740.